Stockscreener 앱 받기
166.23
0.34%
-0.57
시간 외 거래:
168.58
2.35
+1.41%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences stock hits all-time high at 181.3 USD - Investing.com
NBIX|Neurocrine Biosciences Inc|Price:176.825|Chg%:+1.055 - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – HAM:NB3 - TradingView
Net margin % of Neurocrine Biosciences, Inc. – HAM:NB3 - TradingView
Neurocrine Biosciences, Inc. Revenue Breakdown – HAM:NB3 - TradingView
JPMorgan discloses 6.3% Neurocrine stake in 13G/A filing (NBIX) - Stock Titan
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards? - TradingView
Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO - TradingView
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup - ChartMill
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Neurocrine Biosciences (NBIX) Refreshes Leadership On A Narrative That Still Sees Undervaluation - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock - ChartMill
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Leadership Hires In Business And Market Access - simplywall.st
Neurocrine Biosciences Names New Senior Vice Presidents - Contract Pharma
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NEUROCRINE BIOSCIENCES INC. R (NB3.F) Q1 FY2026 earnings call transcript - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine bolsters senior ranks as it builds beyond Ingrezza - The Pharma Letter
NBIX: Neurocrine Biosciences, Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences names three senior vice presidents - Investing.com
Neurocrine Biosciences names three senior vice presidents By Investing.com - Investing.com Nigeria
Neurocrine Hires Market Access Chief, Promotes Two Executives - Stock Titan
Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value - Yahoo Finance
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti To Lead Growth After $2.9 Billion Deal - simplywall.st
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer - Yahoo Finance
NBIX stock consolidates after solid 2024 guidance and Ingrezza growth - Ad-hoc-news.de
Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer - Contract Pharma
Neurocrine Biosciences Inc (NBIX) Stock Up 3.5% and Still Underv - GuruFocus
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer - TradingView
Neurocrine Biosciences names Siddhanti chief business officer By Investing.com - Investing.com South Africa
Neurocrine Biosciences names Siddhanti chief business officer - Investing.com
Neurocrine Biosciences names Samir Siddhanti chief business officer - StreetInsider
Neurocrine executive who led $2.9B Soleno deal gets new role - Stock Titan
Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer - scanx.trade
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup - ChartMill
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - Sahm
Understanding Momentum Shifts in (NBIX) - Stock Traders Daily
Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price - simplywall.st
Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside? - simplywall.st
NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175 - Bitget
Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
NBIX Maintained by Wells Fargo -- Price Target Raised to $200 - GuruFocus
Wells Fargo Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $200 - Moomoo
Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors? - simplywall.st
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening - ChartMill
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199 - Moomoo
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Neurocrine Price Target Raised to $200.00/Share From $155.00 by Truist Securities - Moomoo
NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus
0.40%
2.56%
자본화:
|
볼륨(24시간):